Meet The New Unicorns Minted In September 2022

Twelve companies joined The Crunchbase Unicorn Board in September 2022, adding $19.6 billion in value to the board.

These companies have raised $3.8 billion total in funding with 62% of that amount raised in September 2022.

Search less. Close more.

Grow your revenue with all-in-one prospecting solutions powered by the leader in private-company data.

Six companies are U.S. headquartered. Two hail from India and one each from China, Thailand, Italy and Switzerland. The majority of these companies were founded since 2018, while companies more than a decade old include Molbio Diagnostics and Wealthfront.

Here are the new unicorn companies:

Health care

India-based Molbio Diagnostics, a molecular diagnostics company that builds portable devices to detect TB, HIV and Malaria as well as real-time PCR tests amongst other diseases. The company raised $85 million led by Temasek Holdings which valued the company at $1.6 billion.
New York-based Redesign Health invests in and incubates health care startups. It raised $65 million led by General Catalyst which valued the company at $1.7 billion.
India-based online medicine ordering company 1mg raised a $40 million funding led by Tata Digital which had acquired a majority stake in the company in 2021. The company is valued at $1.2 billion.

Transportation

EV charging infrastructure company TeraWatt Infrastructure, based in San Francisco, raised a $1 billion Series A funding led by Vision Ridge Capital Partners. The company operates charging stations for light-, medium- and heavy-duty vehicles.
China-based Lotus Technology, a subsidiary of Lotus Group, is a developer of electric vehicles, battery and self-driving technologies. It raised funding at a valuation of $4.5 billion.

E-commerce

Bangkok-based on-demand delivery startup LINE MAN Wongnai raised a $265 million Series B that valued it at $1 billion. The funding was led by GIC and LINE Plus Corp.
E-commerce technology company Swiftly, based out of Seattle, helps retailers compete with e-commerce leaders. It raised a $100 million Series B extension funding led by BRV Capital Management valuing the company at $1 billion. Earlier this year in March it raised $100 million led by Wormhole Capital.

Financial services

Milan-based Satispay raised a Series D funding of over $310 million led by New York-based Addition valuing the company at $1 billion. The company counts 3 million users that can bypass credit cards for payments to merchants as well as offering peer-to-peer payments.
San Francisco-based wealth management company Wealthfront mutually terminated a merger agreement with UBS and instead raised a convertible note of $69.7 million from UBS at a $1.4 billion valuation.

Web3

Silicon Valley-based Mysten Labs, founded by former Meta executives, raised a $300 million financing led by FTX Ventures which valued the company at more than $2 billion. The company was founded in 2021 and had the highest count of investors in this round with many active in blockchain including a16z, Coinbase Ventures and Lightspeed Venture Partners among others.
Switzerland-based 21.co, builder of cryptocurrency products, raised $25 million at a value of $2 billion. The funding was led by London-based investment firm Marshall Wace.

Cloud services

Boston-based cloud storage company Wasabi Technologies raised a Series D funding of $125 million funding led by L2 Point which valued the company at $1.1 billion. The company also raised the same amount in debt in order to invest in its infrastructure.

Three exits

Three companies exited the board this past month.

Figma was the single acquisition of a unicorn company in September 2022. Acquired by Adobe for $20 billion, it represents the largest amount paid for a private venture-backed company.

Two life sciences companies from China exited the board via the public markets. MGI Tech builds genomic sequencing machines. It raised $516 million on its IPO on the Shanghai STAR Market. And biopharmaceutical company Biocytogen, which develops gene editing technologies for drug development, raised $60 million on its IPO.

Crunchbase Pro queries listed for this article

All Crunchbase Pro queries are dynamic, with results updating over time. They can be adapted by location and/or timeframe for analysis.

Methodology

Funding rounds included in this report are seed, angel, venture, corporate-venture and private-equity rounds in venture-backed companies. This reflects data in Crunchbase as of Oct. 15, 2022.

The Crunchbase Unicorn Board is a curated list that includes private unicorn companies with post-money valuations of $1 billion or more and is based on Crunchbase data. New companies are added to the Unicorn Board as they reach the $1 billion valuation mark as part of a funding round.

Funding to unicorn companies includes all private financings to companies that are tagged as unicorns, as well as those that have since graduated to The Exited Unicorn Board.

Please note that all funding values are given in U.S. dollars unless otherwise noted. Crunchbase converts foreign currencies to U.S. dollars at the prevailing spot rate from the date funding rounds, acquisitions, IPOs and other financial events are reported. Even if those events were added to Crunchbase long after the event was announced, foreign currency transactions are converted at the historic spot price.

Illustration: Dom Guzman